MedPath

The effect of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome (IBS)

Phase 1
Completed
Conditions
Irritable Bowel Syndrome.
Irritable Bowel Syndrome
k58.0
Registration Number
IRCT20200928048862N1
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with irritable bowel syndrome (IBS)
Mild to moderate score (score less than 11) in the Anxiety and Depression Questionnaire.

Exclusion Criteria

Psychotic patients, bipolar disorder, obsessive-compulsive disorder, substance use in the last 6 months, dementia, suicidal idea
Taking psychotropic drugs in the last 2 weeks
Pregnancy and lactation
age of under 18 years old and over 65 years old
digestive bleeding
Persistent vomiting
Persistent abdominal pain
Unexplained weight loss
Crohn's, celiac disease, colon cancer, seizures, hypertension, angle-closure glaucoma,

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.